Abstract
Background: Multidrug resistance in cancer is the ability of a cancer cell to resist treatment with a wide range of structurally and functionally dissimilar chemotherapeutics. The resistant phenotype could arise in response to several cellular changes that ultimately result in a decrease in intracellular drug accumulation (or effectiveness), either by limiting cellular drug entry, or by expulsion of those molecules that have made it into the cell. Both blocking drug cellular entry and its expulsion are mostly brought about by the cell membrane. Several pharmaceutical excipients (mainly lipids, surfactants and amphililc copolymers) have been reported to reverse multidrug resistance by addressing cell membrane related changes resulting in low intracellular drug levels in resistant cells. These excipients are routinely used in the preparation of lipid based nanoparticles endowing inherent multidrug resistance reversing properties to these nanoparticles.
Methods: In this review, cell membrane alterations resulting in multidrug resistance will be initially reviewed, followed by a discussion of the different types of lipid NPs and the potential held by the excipients used in their preparation in multidrug resistance reversal. Finally, a discussion on how lipid nanoparticles have been engineered and used in different occasions to enable multidrug resistance reversal is included.
Conclusion: The superior role held by lipid nanoparticles in comparison to free excipients will be highlighted.
Keywords: MDR Cancer, liposomes, lipid nanocapsules, solid lipid nanoparticles, nanostructured lipid carriers, multidrug resistance.
Current Pharmaceutical Design
Title:Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Volume: 23 Issue: 43
Author(s): Salma N. Tammam*
Affiliation:
- Pharmaceutical Technology Department, the German University in Cairo (GUC), Cairo,Egypt
Keywords: MDR Cancer, liposomes, lipid nanocapsules, solid lipid nanoparticles, nanostructured lipid carriers, multidrug resistance.
Abstract: Background: Multidrug resistance in cancer is the ability of a cancer cell to resist treatment with a wide range of structurally and functionally dissimilar chemotherapeutics. The resistant phenotype could arise in response to several cellular changes that ultimately result in a decrease in intracellular drug accumulation (or effectiveness), either by limiting cellular drug entry, or by expulsion of those molecules that have made it into the cell. Both blocking drug cellular entry and its expulsion are mostly brought about by the cell membrane. Several pharmaceutical excipients (mainly lipids, surfactants and amphililc copolymers) have been reported to reverse multidrug resistance by addressing cell membrane related changes resulting in low intracellular drug levels in resistant cells. These excipients are routinely used in the preparation of lipid based nanoparticles endowing inherent multidrug resistance reversing properties to these nanoparticles.
Methods: In this review, cell membrane alterations resulting in multidrug resistance will be initially reviewed, followed by a discussion of the different types of lipid NPs and the potential held by the excipients used in their preparation in multidrug resistance reversal. Finally, a discussion on how lipid nanoparticles have been engineered and used in different occasions to enable multidrug resistance reversal is included.
Conclusion: The superior role held by lipid nanoparticles in comparison to free excipients will be highlighted.
Export Options
About this article
Cite this article as:
Tammam N. Salma *, Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer, Current Pharmaceutical Design 2017; 23 (43) . https://dx.doi.org/10.2174/1381612823666171122104738
DOI https://dx.doi.org/10.2174/1381612823666171122104738 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Formation, Properties, and Applications of Polymersomes
Current Pharmaceutical Design Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Hydrolyzed Rutin Decreases Worsening of Anaplasia in Glioblastoma Relapse
CNS & Neurological Disorders - Drug Targets Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets The Targets of Curcumin
Current Drug Targets Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry